Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen to Cut Roughly 11% of Workforce
09:26am, Tuesday, 25'th Jul 2023
The biotech cited the launch of Alzheimer's drug Leqembi as part of its new focus.
Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable
09:24am, Tuesday, 25'th Jul 2023
Biogen reported second-quarter profits that fell 23% while revenue slid 5%, but the biotech's results still came in ahead of views.
Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch
08:39am, Tuesday, 25'th Jul 2023
Biogen, in its second-quarter earnings report, said the plan will result in $700 million in net operating expense savings by 2025.
Biogen tops earnings estimates and says it will shift resources to higher value areas
07:36am, Tuesday, 25'th Jul 2023
Biogen Inc.'s stock BIIB, +0.09% rose 1.1% premarket Tuesday, after the company swept past earnings estimates for the second quarter and said it will shift resources to areas that offer the most value
Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace
07:05am, Tuesday, 25'th Jul 2023
Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, to save costs as the company ramps up the launch of a new Alzheimer's disease drug in efforts to return
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
05:46pm, Monday, 24'th Jul 2023
Biogen stock is trading flat in 2023 ahead of earnings as analysts await news from biotechnology firm about its Alzheimer's drug, Leqembi.
Better Big Biotech Buy: Vertex vs. Biogen
10:09am, Monday, 24'th Jul 2023
Vertex Pharmaceuticals is heading for a big moment -- a regulatory decision on a potential new blockbuster. Biogen recently won regulatory approval for a drug that may become its new growth driver.
4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys
07:54am, Sunday, 23'rd Jul 2023
Barron's Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies, of-which YCharts reported 25 as paying dividends. Barron
Lilly Joins Biogen as Alzheimer's Drugs Finally Emerge
08:03pm, Friday, 21'st Jul 2023
In trials, Biogen and Eli Lilly have shown that their drugs can slow early-stage decline in the disease. It could be a bonanza for patients—and investors.
Final Trades: Charles Schwab, Biogen & more
05:16pm, Thursday, 20'th Jul 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect
12:07pm, Wednesday, 19'th Jul 2023
Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Is Biogen Stock a Buy Now?
08:30am, Wednesday, 19'th Jul 2023
Biogen just earned an important approval for an Alzheimer's disease therapy. Even with this milestone, the biotech still faces serious issues worth considering.
At-home Alzheimer's testing is on the horizon, researchers say
08:04am, Wednesday, 19'th Jul 2023
A simple blood test of the type that can be done at home by a patient or family member has shown promise in detecting Alzheimer's, according to research released Wednesday at the Alzheimer's Associati
Biogen, Eli Lilly likely to split the Alzheimer's drug market, analysts say
08:39am, Tuesday, 18'th Jul 2023
Eli Lilly and Co. LLY, -0.52% and Biogen Inc. BIIB, -0.19% are likely to reach an “equitable split” of the Alzheimer's drug market after Lilly on Monday released more details on its late-stage tri
Should You Buy the Dip With Biogen Stock Right Now?
09:45am, Monday, 17'th Jul 2023
Biogen's newest medicine didn't wow the market upon its approval. There are a handful of stumbling blocks that might hamper the drug's potential.
